Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Zalypsis in Advanced or Metastatic Ewing Family Tumors
2010-022221-15Phase 2
- Sponsor
- PharmaMar
- Start
- Oct 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalypsis in Ewing sarcoma and neuroectodermal tumor, sponsored by PharmaMar. Primary endpoint: Overall response rate.
02
Drugs
zalypsis
03
Conditions
Ewing sarcomaneuroectodermal tumor
Beyond the preview
Go deeper on 2010-022221-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022221-15.